dual glp 1 and gip receptor agonist Main physiological actions of the GLP-1 Dual GIP/GLP-1 receptor agonists: New

The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.

Recent advancementsincluding the approval of oral semaglutide (Rybelsus)have demonstrated the potential for effective oral peptide delivery, though such formulations still face significant pharmacokinetic and formulation-related challenges

Limited evidence suggests that combined SGLT2is/GLP1-RAs therapy can potentially improve most but not all outcomes

These findings support their use as a valuable adjunctive obesity management medication (OMMs) in post-bariatric care, though long-term adherence and cost-effectiveness require further investigation

For example, merely switching from one dose per week (q1wk) to one dose every two weeks (q2wk) maintains roughly 75% of the weight loss